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OBJECTIVES: Febrile neutropenia (FN) is a common side effect
of cancer chemotherapy that considerably increases the total cost
of management. Standard clinical practice of treating FN consists
of either immediate hospitalization or ambulatory treatment
depending on the patient’s risk of complications and co-
morbidities as evaluated by the MASCC score (Multinational
Association for Supportive Care in Cancer). The objective of this
study was to evaluate the budgetary impact of in-patient man-
agement of patients with FN. METHODS: The study prospec-
tively included 102 consecutive patients with a solid tumor
admitted with FN to the emergency department of Institut
Gustave Roussy between March and October 2006. Patients
were treated according to standard clinical practice. Costs were
analyzed from the hospital perspective. The cost of each stay was
extracted from the hospital cost accounting system and com-
pared to the reimbursement tariff received from Diagnosis
Related Group (DRG). The observed length of hospital stay was
also compared with the mean length of stay in the DRG.
RESULTS: Mean (SD) patient age was 50.7  14.7 years and 68
patients (66.6%) were women. For all patients, FN followed the
administration of chemotherapy. Fourteen (13.7%) patients were
treated on an out-patient basis and were excluded from this
analysis. The mean length of stay of the 88 in-patients was
estimated to be 6.2  7.2 days. The mean cost per stay was
estimated to be €6096 (median: €3796), whereas the mean tariff
reimbursement was €5125 (median: €4319). CONCLUSIONS:
On average, the management of in-patients with FN is in deﬁcit
by €971 per stay at Institut Gustave Roussy. Five speciﬁc patient
stays were largely responsible for the global deﬁcit, as in these
cases, the duration of hospitalisation was longer than that speci-
ﬁed in the DRG.
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OBJECTIVES: Trastuzumab, a monoclonal antibody, is used in
the adjuvant treatment of HER2+ breast cancer. Several different
doses and schedules are used, but the optimal duration or dosing
frequency of trastuzumab is not known. Most clinical evidence is
from 1-year treatment, but shorter 9-week treatment has also
been studied. The aim of this study was to evaluate the budget
impact of the different treatment protocols. METHODS: The
perspective of the study was of a single hospital district with
250,000 inhabitants (i.e. payer), in which all trastuzumab treat-
ment is concentrated to one hospital. Clinical experts described
the current treatment, which included both short and long
administration of trastuzumab. A budget impact model, which
took into account the number of patients, HER2+ prevalence,
length and cost of treatment, as well as effectiveness, was created.
Estimates concerning distant disease free survival (DDFS) were
derived from the published data of FinHer-trial. The effectiveness
of both long- and short-term treatment was assumed to be equal.
Treatment costs for different stages of breast cancer were inden-
tiﬁed. RESULTS: In one year, adjuvant trastuzumab treatment
caused a total net budget impact of €119,000 and €619,000 if all
patients were treated with either short or prolonged therapy
alone, respectively. The difference was around €500,000 in one
year. However, in a 4-year period the impact of using long instead
of short therapy was €2 million. The annual incidence of breast
cancer in the area was 176 and the prevalence of HER2+ was
12%. Adjuvant treatment with trastuzumab prolongs DDFS and
thus reduces the need of treatment of advanced breast cancer.
CONCLUSIONS: Length of treatment had a substantial inﬂu-
ence on costs. Investments in ﬁnding optimal treatment strategy
for expensive medications may appear highly cost-effective.
Future trials will show to what extent the duration of trastu-
zumab treatment affects the effectiveness of the therapy.
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